Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

Breast Neoplasm Clinical Trial

— MERIBEL  

Official title:

A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02061085
• Other study ID #: OBU-SW-H-02
• Secondary ID: 2012-004463-41
• Status: Completed
• Phase: Phase 2
• Start date: July 2013
• Est. completion date: December 2015

Study information

• Verified date: March 2015
• Source: MedSIR
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage.

The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed metastatic breast cancer HER2 negative, stage IIIb/IV

• Previous history of early disease (stage I-IIIb), surgically resected and treated with standard chemotherapy for at least 12 weeks at which included a taxane or ixabepilone

• Patients must have progressed in the 36 months after treatment with taxanes or ixabepilone.

• Age = 18 years

• Given written informed consent

• Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1

• Patients must have recovered from toxicities related with previous treatment (CTC = 1)

• Measurable or evaluable disease (RECIST 1.1)

• Adequate bone marrow function

• Adequate hepatic function

• Adequate renal function

• Life expectancy = 3 months

Exclusion Criteria:

• Breast cancer patients initially diagnosed with local disease advanced or metastatic disease.

• Patients who have previously received cytotoxic therapy Hormone therapy permitted if the patients have interrupted it at least two weeks before the start of the study treatment.

• Major surgery or significant traumatic injury during the 4 weeks prior to study treatment or patients who may require major surgery during the assay.

• Brain metastases or leptomeningeal uncontrolled.

• Serious medical condition and / or not properly controlled (unstable angina, lung function severe impaired, uncontrolled diabetes, active serious infection,liver disease, HIV seropositivity, active bleeding diathesis)

• Other malignancies in the last three years, except: cervical carcinoma in situ, basal cell carcinoma or squamous cell skin carcinoma,that have been properly treated

• Patients who are pregnant or breastfeeding, or adults with reproductive capacity wich are not using effective contraception.

• Patients receiving chronic treatment with systemic corticosteroids or other immunosuppressive drugs (except corticosteroids with a daily dose equivalent to prednisone = 20mg on a stable dose regimen one minimum of 4 weeks prior to study entry. Topical and inhaled corticosteroids are allowed

• Active alcoholism or drugs addiction documented.

• Prior history of noncompliance with medical regimens

• Patients who do not want or can not comply with the study protocol

Related Conditions & MeSH terms

• Breast Neoplasm
• Breast Neoplasms
• Metastasis
• Neoplasm Metastasis

Intervention

Drug:
• Eribulina

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
MedSIR

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median time to disease progression and treatment benefit variable		Up to two years from the last dose
Secondary	Objective response rate		Up to one year from the first dose
Secondary	Clinical benefit rate		Up to one year from the first dose
Secondary	Time until progression after the treatment		Up to two years from the last dose
Secondary	Median duration of response		Up to one year from the first dose
Secondary	Safety of eribulin in terms of adverse reactions		Up to two years form the last dose
Secondary	Utility functional hepatic levels as criteria for dose modifications instead of the Child-Pugh classification system for the assessment of liver involvement		Up to one year form the last dose